Indian State FDA Calls For Probe Into ‘Exorbitant’ Stent Costs
This article was originally published in PharmAsia News
Executive Summary
Cardiac stent makers are under the regulatory glare in India on allegations of charging exorbitantly to patients. A state level regulator has written to the national pricing watchdog to clamp down.